Smith Dean G
Department of Health Management & Policy, University of Michigan, 109 Observatory, Ann Arbor, MI 48109-2029, USA.
Curr Atheroscler Rep. 2003 Jan;5(1):67-72. doi: 10.1007/s11883-003-0070-6.
The widespread use and high cost of lipid-lowering drugs have resulted in numerous investigations of their cost effectiveness. Pharmacoeconomic analyses have considered initiation of treatment, maintenance therapy, and long-term outcomes of lipid-lowering therapy. Analyses have yielded a number of consistent messages, but the story continues to evolve as new trials, models, and drugs are introduced. Certain medications are more efficacious and associated with more cost-effective lipid-lowering therapy initiation. Other medications are lower priced and may be more cost effective for maintenance, contingent upon having achieved lipid-lowering goals. Finally, some medications have proven long-term cost effectiveness in trials and comparative cost effectiveness in models. Research is certain to further our understanding of the costs of lipid-lowering therapy and the methods needed to optimize expenditures.
降脂药物的广泛使用及其高昂成本引发了对其成本效益的大量研究。药物经济学分析考虑了降脂治疗的起始、维持治疗以及长期疗效。这些分析得出了一些一致的结论,但随着新试验、模型和药物的推出,情况仍在不断变化。某些药物更有效,且与更具成本效益的降脂治疗起始相关。其他药物价格较低,对于维持治疗而言,在已实现降脂目标的情况下可能更具成本效益。最后,一些药物在试验中已证明具有长期成本效益,在模型中也具有比较成本效益。研究必将进一步加深我们对降脂治疗成本以及优化支出所需方法的理解。